Navigate Fool.com
Will MNKD beat
the market?

MannKind Corp (NASDAQ: MNKD)

Community Rating: 2 Stars: Unattractive

9.77 0.14 (1.45%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $9.66
Previous Close $9.63
Daily Range $9.65 - $10.10
52-Week Range $3.80 - $11.48
Market Cap $3.8B
P/E Ratio -15.29
Dividend (Yield) $0.00 (0.0%)
Volume 6,358,408
Average Daily Volume 10,859,247
Current FY EPS -$0.37

How do you think MNKD
will perform against the market?

Top MNKD Bull/Bear Pitches


Investinguppy (0)
Submitted June 18, 2014

Inhalable insulin might become a game changer. The technosphere technology might also be useful for a number of different drugs, and the CEO Al Mann has experience bringing medical devices to market … More

0 Replies Reply Report this Post

usubanas (< 20)
Submitted March 28, 2014

predict FDA panel will vote negatively next week.

1 Replies Reply Report this Post

News & Commentary

3 Longtime Losers About to See Green?

These 3 biotechs have lost tons of money every year so far in the 21st century. But could profits be on the horizon?

4 Stocks to Watch This Week

Let's look at the stocks that will be making news in the week ahead.

Is This MannKind's Greatest Risk?

MannKind won FDA approval for Afrezza but still faces risks. Is this one the biggest of all?

1 Key Question Remains after MannKind's Giant Leap

After FDA approval, now comes the hard part

Thirteen Analyst Stocks Under $10 With Huge Upside Potential

3 Things to Look for in MannKind's Partnership

Merck would be a perfect partner for MannKind; Novo Nordisk and Eli Lilly are likely out.

Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire

Today's top stories in biotech and health care.

MannKind Poll Points to Bias That Stock Will Rise Above $15 into 2015

Should AstraZeneca Buy MannKind?

AstraZeneca (AZN) hopes to grow its diabetes revenue in the coming years and could benefit from adding MannKind's Afrezza to its product line up.

Top Analyst Upgrades and Downgrades: Juniper Networks, Netflix, MannKind, Xerox and More

See More MNKD News...





MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks